Aldeyra Therapeutics discovers and develops innovative therapies designed to treat immune-mediated diseases. Our approach is to develop therapies that modulate immunological systems, instead of inhibiting or activating single targets, with the goal of optimizing multiple pathways at once while minimizing toxicity. Two of our lead product candidates, reproxalap and ADX-629, target pre-cytokine, systems-based mediators of inflammation known as RASP (reactive aldehyde species). Reproxalap is in Phase 3 clinical trials in patients with dry eye disease and allergic conjunctivitis. ADX-629, an orally administered RASP modulator, is in Phase 2 proof-of-concept clinical trials in psoriasis, asthma, and COVID-19. Our pipeline also includes ADX-2191 (intravitreal methotrexate 0.8%), in development for the prevention of proliferative vitreoretinopathy and the treatment of retinitis pigmentosa and primary vitreoretinal lymphoma.
Location: United States, Massachusetts, Lexington
Employees: 11-50
Phone: +1 781-761-4904
Total raised: $7.79M
Founded date: 2004
Investors 2
| Date | Name | Website |
| - | Domain Ass... | domainvc.c... |
| - | Hercules C... | htgc.com |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 15.01.2015 | - | $7.79M | - |
Mentions in press and media 11
| Date | Title | Description | Source |
| 12.07.2022 | 'Approvability has been put to bed': Aldeyra says eye dr... | Aldeyra’s attempt at treating dry eye disease has seen a few ups and downs in recent years, but ... | endpts.com... |
| 02.02.2022 | Aldeyra Therapeutics Announces Publication of Phase 2 Clinic... | ModelLEXINGTON, Mass. - Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company... | marketscre... |
| 09.11.2021 | Aldeyra Therapeutics Announces Completion of Enrollment in P... | Aldeyra Therapeutics Announces Completion of Enrollment in Phase 3 TRANQUILITY Trial in Patients wit... | marketscre... |
| 02.11.2021 | Aldeyra Therapeutics Corporate Overview – November 2021 | November 2021 CORPORATE OVERVIEW Innovative Approaches to Regulating Immune Response Nasdaq: ALDX... | marketscre... |
| 28.10.2021 | Aldeyra Therapeutics Reports Third-Quarter 2021 Financial Re... | Aldeyra Therapeutics Reports Third-Quarter 2021 Financial Results and Recent Corporate Highlights C... | marketscre... |
| 28.10.2021 | Aldeyra Therapeutics Corporate Overview – October 2021 | October 2021 CORPORATE OVERVIEW Innovative Approaches to Regulating Immune Response Nasdaq: ALDX ... | marketscre... |
| 14.05.2021 | Aldeyra Therapeutics : Corporate Overview – May 2021 | May 2021 CORPORATE OVERVIEW Innovative Approaches to Regulating Immune Response Nasdaq: ALDX © A... | marketscre... |
| 14.05.2021 | ALDEYRA THERAPEUTICS, INC. Aldeyra Therapeutics : Corporate... | May 2021 CORPORATE OVERVIEW Innovative Approaches to Regulating Immune Response Nasdaq: ALDX © A... | marketscre... |
| 29.11.2016 | Allergy treatments enter a new era — with a focus on stoppin... | Allergy treatments haven’t advanced much in decades, even as hundreds of millions around the world s... | statnews.c... |
| 29.06.2016 | The biotech IPO feast flags as investors lose their appeti... | There was a time after the 2008 crash that biotech IPOs were about as popular as snow in March. B... | endpts.com... |
Show more